Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:56 PM
Ignite Modification Date:
2025-12-24 @ 2:56 PM
NCT ID:
NCT04731259
Eligibility Criteria:
Inclusion Criteria:
* Subject must be at least 18 years of age inclusive, at the time of signing the informed consent
* Subjects with a current diagnosis of cancer
* IGA grade of 0 on the face
* Life expectancy, in the Investigator's opinion, greater than 12 weeks
* Plan to initiate treatment with one of the following EGFRI drugs (other treatments may be considered after consultation with the Sponsor): Cetuximab or Panitumumab or erlotinib
* Able to use Dove sensitive skin body wash for the duration of the treatment period.
* Acceptable and willing to delay start of EGFRI therapy until study eligibility is determined
* Anticipated to continue EGFRI therapy for at least 28 days after the first application of study medication
* Male and/or female
* Contraceptive use by men or women consistent with the EGFRI treatment package insert regarding the methods of contraception for those participating in clinical studies
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.
Exclusion Criteria:
* Active bacterial skin infections on the face
* Inter-current illness that in the Investigator's opinion puts the subject at undue risk by study participation or interfere with the study conduct or evaluations
* Pregnant women
* EGFRI therapy within the previous 12 weeks
* Radiation therapy exposure to the face within the previous 8 weeks
* Use of topical steroids on the face within the previous 4 weeks
* Use of systemic antibiotics or topical antibiotics on the face in the previous 7 days
* Participation in an investigational clinical study in which administration of an investigational study medication occurred with the previous 30 days
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04731259
Study Brief:
Protocol Section:
NCT04731259